RYVU Therapeutics S.A. Logo

RYVU Therapeutics S.A.

Clinical-stage drug discovery company developing novel small molecule therapies for oncology.

RVU | WAR

Overview

Corporate Details

ISIN(s):
PLSELVT00013 (+2 more)
LEI:
2594003WO9Q9HHAFL031
Country:
Poland
Address:
Kraków Leona Henryka Sternbacha 2, 30-394 Kraków
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. The company's mission is to develop innovative cancer treatments by targeting key biological pathways, including kinase, synthetic lethality, and immuno-oncology. Its pipeline features multiple candidates advancing through preclinical and clinical stages, such as RVU120 for hematological malignancies and myelofibrosis, and Dapolsertib for lymphoma. Founded in 2007 (formerly as Selvita S.A.), Ryvu leverages its scientific expertise to create precise therapies aimed at improving patient outcomes and quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 17:03
Audit Report / Information
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeu…
English 154.9 KB
2025-09-18 17:03
Audit Report / Information
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeu…
Polish 159.6 KB
2025-09-18 17:03
Interim Report
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 ENG
English 4.4 MB
2025-09-18 17:03
Interim Report
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 ENG
English 3.8 MB
2025-09-18 17:03
Regulatory News Service
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL xades
Polish 75.0 KB
2025-09-18 17:03
Regulatory News Service
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL xhtml
Polish 6.8 MB
2025-09-18 17:03
Interim Report
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL
Polish 4.6 MB
2025-09-18 17:03
Regulatory News Service
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 PL xades
Polish 5.8 MB
2025-09-18 17:03
Regulatory News Service
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 PL xhtml
Polish 5.7 MB
2025-09-18 17:03
Interim Report
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 PL
Polish 4.1 MB
2025-09-09 11:32
Regulatory News Service
RVU120 w nowym, zainicjowanym przez badacza, badaniu fazy I, w leczeniu pacjent…
English 2.9 KB
2025-09-09 11:32
Regulatory News Service
RVU120 w nowym, zainicjowanym przez badacza, badaniu fazy I, w leczeniu pacjent…
Polish 2.3 KB
2025-06-26 15:56
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
English 2.2 KB
2025-06-26 15:56
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish 1.5 KB
2025-06-26 15:50
Post-Annual General Meeting Information
Uchwaly ZWZ_2025
Polish 161.9 KB

Automate Your Workflow. Get a real-time feed of all RYVU Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for RYVU Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom OBD
Pharnext Logo France ALPHA
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.